Daniel K Turner

Bio

Mr. Turner has 25 years of experience as an entrepreneur, operating manager and venture capitalist. He founded Montreux and has been a General Partner/Managing Member since 1993. Immediately prior to founding Montreux, Mr. Turner was a Principal in the Turnaround Group for Berkeley International. Previously, he was the founding Chief Financial Officer of Oclassen Pharmaceuticals, a specialty pharmaceutical company focused in dermatology, which merged with Watson Pharmaceuticals (NYSE: WPI) in 1997. Mr. Turner started his career with Price Waterhouse in the high technology group. He holds a B.S. from California State University, Sacramento and attended the M.B.A. program at the Haas School of Business at the University of California, Berkeley, where he has established the Turner Fellowship. Mr. Turner is a Certified Public Accountant. Mr. Turner is a member of the board of directors of OREXIGEN (NASDAQ: OREX), Renal CarePartners, and Tobira Therapeutics. Mr. Turner previously served as Montreux’s representative to the board of directors of Cerexa (sold to Forest Laboratories, 2007), NovaCardia (sold to Merck, 2007), Peninsula Pharmaceuticals (sold to Johnson & Johnson, 2005). In addition to his activities at Montreux, Mr. Turner is a member of the Board of Trustees at Woodside Priory School and a member of the Advisory Board of the Lester Center at the Haas School of Business at the University of California, Berkeley.